The aim of investigation was to study efficiency of trimetazidine in patients with hypertrophic cardiomyopathy (HCMP). The study included 38 patients with HCMP (38.4±2.9 years), 74% – males. The investigations included 12-lead ECG, echocardiography, Holter ECG monitoring, exercise test, subjective evaluation of the anginal pain. The patients from the first group (n=20) received trimetazidine 70 mg daily in addition to carvedilol, second group (n=18) – only traditional treatment. The follow-up duration was 3 months. More that half of patients had angina symptoms. Combined treatment with carvedilol and trimetazidine decreased angina and improved exercise tolerance.